Figure 2
Urine assays showed a significant increase in CO3-610 levels at all time points between bleomycin- and control PBS-treated mice. The diagram shows the assay result at each time point (n = 7 PBS, n = 13 bleomycin-treated per termination point) and the mean CO3-610 levels across all time points (n = 28 PBS, n = 52 bleomycin-treated mice). At 2 weeks, (mean PBS 5.05 ng/ml, Bleomycin 8.04 ng/ml) P = 0.0008, 4 weeks (mean PBS 5.68 ng/ml, Bleomycin 12.1 ng/ml) P < 0.0001, 6 weeks (mean PBS 5.66 ng/ml, bleomycin 13.4 ng/ml) P < 0.0001, 8 weeks (mean PBS 5.41 ng/ml, bleomycin 13.9 ng/ml) P < 0.0001 and overall P < 0.0001 (A). CO3-610 Western blots image with control and bleomycin samples after 2 and 8 weeks treatment, and corresponding beta Actin loading controls (B). CO3-610 densitometry measurements for all time points (n = 7 PBS and n = 13 Bleomycin treated per termination point) and collective CO3-610 levels (n = 28 PBS and n = 52 bleomycin-treated mice) showing a statistically significant increase of CO3-610 levels (P < 0.0001) (C). CO3-610 levels found in the urine assay were correlated with skin thickness progression, and therefore total collagen deposition (r = 0.4883, R2 = 0.2384) (D). The correlation between CO3-610 levels detected by the ELISA urine assay and Western blot densitometry measurements was statistically significant (r = 0.6528, P < 0.0001) (E).